

 **NOVARTIS** PATENTED MEDICINE
PRICES REVIEW BOARD

Jean-Charles Hébert
Vice President
Health Policy and
Market Access

Novartis Pharmaceuticals Canada Inc.
385 Bouchard Blvd.
Dorval QC Canada H9S 1A9

Tel 1 (514) 631-7880, ext. 7856
Fax 1 (514) 631-0307

Internet: jean-charles.hebert@novartis.com

2005 APR 20 PM 4 06

CONSEIL D'EXAMEN
DU PRIX DES
MÉDICAMENTS BREVETÉS

April 18, 2005

PUROLATOR

Sylvie Dupont
Secretary of the Board
Patented Medicine Prices Review Board
Box L40 - Standard Life Centre
333 Laurier Avenue West, Suite 1400
Ottawa, Ontario
K1P 1C1

3225-3-13

050428


Subject: Proposal to Amend the Patented Medicines Regulations 1994 (the Regulations)

Dear Ms Dupont,

In February 2005 the Patented Medicine Prices Review Board issued a proposal to amend the *Patented Medicines Regulations, 1994* (the *Regulations*) and invited comments from stakeholders. Novartis reviewed the PMPRB proposal and the response communicated by Rx&D, our Association of Canada's Research-Based Pharmaceutical Companies (Rx&D).

Novartis Pharma Canada Inc. supports Rx&D's position on the PMPRB proposed amendments and welcomes any comments that PMPRB might have.

Sincerely,


Jean-Charles Hébert